首页> 美国卫生研究院文献>PLoS Clinical Trials >Dimerization with Cannabinoid Receptors Allosterically Modulates Delta Opioid Receptor Activity during Neuropathic Pain
【2h】

Dimerization with Cannabinoid Receptors Allosterically Modulates Delta Opioid Receptor Activity during Neuropathic Pain

机译:与大麻素受体的二聚化变构调节神经性疼痛期间的阿片类药物受体活性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The diversity of receptor signaling is increased by receptor heteromerization leading to dynamic regulation of receptor function. While a number of studies have demonstrated that family A G-protein-coupled receptors are capable of forming heteromers in vitro, the role of these heteromers in normal physiology and disease has been poorly explored. In this study, direct interactions between CB1 cannabinoid and delta opioid receptors in the brain were examined. Additionally, regulation of heteromer levels and signaling in a rodent model of neuropathic pain was explored. First we examined changes in the expression, function and interaction of these receptors in the cerebral cortex of rats with a peripheral nerve lesion that resulted in neuropathic pain. We found that, following the peripheral nerve lesion, the expression of both cannabinoid type 1 receptor (CB1R) and the delta opioid receptor (DOR) are increased in select brain regions. Concomitantly, an increase in CB1R activity and decrease in DOR activity was observed. We hypothesize that this decrease in DOR activity could be due to heteromeric interactions between these two receptors. Using a CB1R-DOR heteromer-specific antibody, we found increased levels of CB1R-DOR heteromer protein in the cortex of neuropathic animals. We subsequently examined the functionality of these heteromers by testing whether low, non-signaling doses of CB1R ligands influenced DOR signaling in the cortex. We found that, in cortical membranes from animals that experienced neuropathic pain, non-signaling doses of CB1R ligands significantly enhanced DOR activity. Moreover, this activity is selectively blocked by a heteromer-specific antibody. Together, these results demonstrate an important role for CB1R-DOR heteromers in altered cortical function of DOR during neuropathic pain. Moreover, they suggest the possibility that a novel heteromer-directed therapeutic strategy for enhancing DOR activity, could potentially be employed to reduce anxiety associated with chronic pain.
机译:受体信号转导的多样性通过受体异聚而增加,导致受体功能的动态调节。尽管许多研究表明,A家族G蛋白偶联受体能够在体外形成异源异构体,但这些异源异构体在正常生理和疾病中的作用尚未得到充分研究。在这项研究中,检查了大脑中CB1大麻素和阿片类药物受体之间的直接相互作用。另外,探索了在神经性疼痛的啮齿动物模型中异聚体水平的调节和信号传导。首先,我们研究了周围神经病变导致神经性疼痛的大鼠大脑皮质中这些受体的表达,功能和相互作用的变化。我们发现,在周围神经病变后,在选定的大脑区域,大麻素1型受体(CB1R)和δ阿片受体(DOR)的表达均增加。伴随地,观察到CB1R活性增加和DOR活性降低。我们假设DOR活性的下降可能是由于这两个受体之间的异聚相互作用。使用CB1R-DOR异源异构体特异性抗体,我们发现神经性动物皮层中CB1R-DOR异源单体蛋白水平增加。随后,我们通过测试低,无信号剂量的CB1R配体是否影响皮层中的DOR信号传导来检查这些杂聚体的功能。我们发现,在经历神经性疼痛的动物的皮质膜中,无信号剂量的CB1R配体显着增强了DOR活性。而且,该活性被异源特异性抗体选择性地阻断。总之,这些结果证明了CB1R-DOR异聚体在神经性疼痛期间在DOR皮质功能改变中具有重要作用。此外,他们提出了一种新的针对异物的增强DOR活性的治疗策略,有可能被用来减少与慢性疼痛相关的焦虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号